Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice Guidelines

Updates in Extended Endocrine Therapy for HR+ Breast Cancer | ASCO21 & National Practice GuidelinesПодробнее

Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast CancerПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast CancerПодробнее

Adjuvant endocrine therapy for breast cancer: optimal durations and regimensПодробнее

Breast Cancer Index, Extended Endocrine Therapy | Elizabeth Ott, PA | 2022 West Oncology APP UpdatesПодробнее

Standardizing Extended Endocrine Therapy RecommendationsПодробнее

The Only Guideline Recognized Test to Predict Extended Endocrine Therapy BenefitПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Which women with HR+, early-stage breast cancer benefit from extended endocrine therapy?Подробнее

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast CancerПодробнее

Diagnostics: Genomics for Treatment Planning | Reshma Mahtani, DO | 2022 Review and Renew SedonaПодробнее

E2112: endocrine therapy plus entinostat in HR+ advanced breast cancerПодробнее

Breast Cancer update - WebinarПодробнее

Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cancer GuidelineПодробнее

Adjuvant Treatment for Early Stage Hormone Positive Breast Cancer: Role of Genomic SignaturesПодробнее

Dr. Joseph Sparano on the Role of Endocrine Therapy in Breast CancerПодробнее

Extended Endocrine Therapy: Who Will Benefit?Подробнее

BCI: A Unique, Guideline-Recognized Test to Predict Benefit of Extended Endocrine TherapyПодробнее

ASCO Guidelines: Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cance...Подробнее